Cutaneous Neurofibroma Clinical Trial
Official title:
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05005845 -
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
|
Phase 2 | |
| Active, not recruiting |
NCT05438290 -
DPCP to Treat Cutaneous Neurofibromas Associated With NF1
|
Phase 1 | |
| Not yet recruiting |
NCT03105258 -
Selumetinib Pilot Study for Cutaneous Neurofibromas
|
Phase 2 | |
| Recruiting |
NCT05581511 -
Natural History Study of Cutaneous Neurofibromas in People With NF1
|
||
| Completed |
NCT03090971 -
Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
|
Phase 2 | |
| Recruiting |
NCT06159166 -
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
|
Phase 1/Phase 2 | |
| Completed |
NCT02839720 -
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
|
Phase 2 | |
| Completed |
NCT04435665 -
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
|
Phase 2 | |
| Active, not recruiting |
NCT05119582 -
HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy
|
N/A |